Form D: Bioincept $7.28 million Financing. Jacqueline Barnea Published Dec 1 SEC Filing

Biotechnology Bioincept Llc - Jacqueline Barnea

Bioincept Financing

Bioincept Llc, Limited Liability Company just had published form D regarding $7.28 million equity financing. The date of first sale was 2016-09-15. Bioincept was able to fundraise $7.28 million. That is 100.00% of the fundraising. The total fundraising amount was $7.28 million. The financing document was filed on 2016-12-01. The reason for the financing was: unspecified.

Bioincept is based in New Jersey. The filler’s business is Biotechnology. The SEC form was submitted by Jacqueline Barnea President and CEO. The company was incorporated more than five years ago. The filler’s address is: 1697 Lark Lane, Cherry Hill, Nj, New Jersey, 08003. Jacqueline H. Barnea is the related person in the form and it has address: C/O Bioincept Llc, 1697 Lark Lane, Cherry Hill, Nj, New Jersey, 08003. Link to Bioincept Filing: 000119248216000761.

Analysis of Bioincept Offering

On average, startups in the Biotechnology sector, sell 73.77% of the total offering amount. Bioincept sold 100.00% of the offering. Could this mean that the trust in Bioincept is high? The average financing size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 136.52% bigger than the average for companies in the Biotechnology sector. The minimum investment for this offering is set at $64895. If you know more about the reasons for the fundraising, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Bioincept Also

The Form D signed by Jacqueline Barnea might help Bioincept Llc’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment